Previous 10 | Next 10 |
home / stock / lzagf / lzagf news
2024-01-26 11:52:39 ET More on Lonza Lonza not planning to manufacture GLP-1 drugs: report Historical earnings data for Lonza Group Dividend scorecard for Lonza Group Financial information for Lonza Group Seeking Alpha’s Quant Rating on Lonza G...
2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...
2023-10-16 10:34:11 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...
2023-10-05 04:55:58 ET Summary Lonza's CEO departure raises questions about business continuity, but we believe the stock price already reflects the worst-case scenario. Lower CAPEX and an ongoing buyback program (with potential M&A flexibility) are a plus given a 'higher for ...
2023-09-24 12:00:08 ET More on COVID vaccine makers Moderna: Covid Curse Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Novavax: Sell A Covid Bounce Barclays projects over $5B COVID booster sales in fall 2023 Vaccine makers...
2023-09-19 10:56:26 ET More on Moderna Moderna: Buy Before The Fall Covid-19 Wave Moderna slips 8% as Pfizer COVID shot forecast weighs on shares Pfizer sees 24% of eligible Americans getting COVID-19 boosters Pfizer, Moderna And COVID Vaccine Patents: Implic...
2023-09-08 00:03:09 ET Summary The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. ...
2023-07-24 05:26:00 ET Summary Lonza Group lowered its 2023 guidance, reducing its forecast and EBITDA margin outlook. This cut implied an H2 margin deterioration. Despite that, the company's 2024 outlook remains positive, and we see support for the Contract Development and Manufa...
2023-07-21 13:10:24 ET Lonza Group AG (LZAGY) Q2 2023 Earnings Conference Call July 21, 2023, 08:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosser - JPMorgan James Quigley - Mor...
2023-06-30 03:41:20 ET Summary Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the healthcare sector. We positively favor Lonza's capital allocation priorities. In addition, the compa...
News, Short Squeeze, Breakout and More Instantly...
Lonza Group AG Company Name:
LZAGF Stock Symbol:
OTCMKTS Market:
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today ...
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY). Under...